Abstract
The vascular endothelial growth factor (VEGF) and its receptors are the major modulators to form a new vascular network from pre-existing blood vessels, a process known as angiogenesis. Anti-VEGF therapies are a reality and an option for the treatment of angiogenesis-dependent diseases, such as cancer and some retinopathies. These therapies have as target the inhibition of VEGF or of the …